Emerald Health Therapeutics (TSXV: EMH) is Stenocare’s new supplier of choice following the fallout earlier this year with Canntrust Holdings (TSX: TRST) (NYSE:CTST). Under the newly signed agreement, Emerald Health will become a supplier for Stenocare for both Denmark and other international markets.
Within the release issued this morning, it was revealed that Emerald Health has been working with Stenocare in the background since September to pre-qualify Emerald’s production methods and products. Stenocare had terminated its previous agreement with Canntrust during that same month, as a result of the firm losing its production licenses for illegally growing cannabis in unlicensed rooms at their Pelham, Ontario facility. It was also previously discovered that such illegally grown product had been shipped to Stenocare in Denmark, resulting in Stenocare being required to issue a recall on its products.
Under the new agreement Emerald will progress towards having multiple oil products approved for international export. Stenocare and Emerald will now progress towards receiving approval from the Danish Medicines Agency for approval for Emerald’s products in the Danish Medical Cannabis Pilot Programme. No timeline was given for an estimated approval date.
As Emerald ramps up production at its two recently fully-licensed production facilities, we look forward to fulfilling our commitment to STENOCARE and helping them to serve Danish patients.Riaz Bandali, CEO of Emerald
Anticipated export quantities were not provided within today’s news release.
Emerald Health Therapeutics closed yesterdays session at $0.72 on the TSX Venture.
Information for this briefing was found via Sedar and Emerald Health Therapeutics. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.